Why Deuteration? Process, Therapeutic Utility, and Developments

Why Deuteration? Process, Therapeutic Utility, and Developments

On-Demand Webcast
Program Description

A substantial need persists for pharmacologic therapies that offer effective symptom control with improved pharmacokinetic properties, fewer adverse reactions, and improved tolerance. Chronic disorders such as hyperkinetic movement disorders, Alzheimer’s agitation, diabetic nephropathy, schizophrenia, and major depressive disorder can be severely debilitating. Without known cures, treatment of these disorders relies heavily on symptomatic control – a challenge with currently available therapies. Deuteration can improve the pharmacokinetic and toxicological properties of many common and available agents, thereby addressing the many limitations of current therapies and substantial unmet needs that persist within medical treatment. This activity will discuss its process, utility within drug development (i.e. prolonged plasma half-life, reduced metabolic variability, fewer lower total daily doses, improved tolerance, etc.), and clinical trials investigating the efficacy of deuterium-containing agents within specific therapeutic areas.

Webcast Access

Click here to access the webcast and for complete accreditation information.

This activity is hosted on the MyCME website. Viewers will need to create an account before accessing the webcast. Please visit www.mycme.com or the above access link for more information.

Faculty

Samuel Frank, MD
Associate Professor of Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Director, Huntington’s Disease Society of America (HDSA) Center of Excellence at BIDMC
Boston, MA

Accreditation

In support of improving patient care, North American Center for Continuing Medical Edu­cation (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

CME

NACCME designates this live activity for a maximum of .25 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CNE

This continuing nurse education activity awards .25 contact hour.

CPE

This enduring activity is approved for 0.25 contact hour (0.025 CEUs) of continuing pharmacy education (JA0006201-0000-18-173-H01-P). 

This educational activity is a knowledge-based activity.

Grant Support

This activity has been supported through an independent educational grant from Teva Pharmaceuticals.